Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results , with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue ...
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations , with sales up 6% year on year to $174.2 million.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback